FLEURY ON NM
Fleury S.A. provides medical services in various areas, including diagnostic, treatment, clinical analysis, health management, and more. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It offers laboratory tests, imaging services, genomics, and other healthcare solutions. Fleury also has a digital healthcare platform called Saúde I for teleconsultations, test results, and electronic medical records.
Overview
Strengths
- With an appreciation Potential of 139.95%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (13.25) is lower than the sector mean (67.88).
- Price to book ratio (1.54) is lower than the sector mean (9.96).
- The company has high returns. ROIC (20.55%) is higher than the sector mean (7.40%).
- EV/EBITDA (5.73) is lower than the sector mean (36.02).
- EV/EBIT (9.29) is lower than the sector mean.
- Price to free cash flow (5.66) is lower than the sector mean.
- Strong EBITDA Margin of 27.83%.
Weaknesses
- The company has high debt. Net Debt to EBITDA Ratio (1.91) is higher than the sector mean.
Key Financial Data